TABLE 1.

Median and 12‐month survival stratified by patient characteristics

	Number (%)	p	Median survival (months)	12‐month survival
Overall population			9.3	41.9%
Age		0.23
<60	80 (22.5%)		9.3	40.3%
≥60	275 (77.7%)		9.2	42.5%
Gender		0.43
Male	179 (50.4%)		8.6	41.5%
Female	176 (49.6%)		9.3	42.3%
ECOG performance status		<0.001
0–1	178 (50.1%)		15.4	56.3%
2	108 (30.4%)		6.4	35.6%
3–4	69 (19.5%)		2.5	8.4%
Albumin		<0.001
≥3.4	153 (43.1%)		14.4	54.7%
2.4–3.3	128 (36.1%)		5.5	24.5%
<2.4	24 (6.8%)		2.5	4.9%
Unknown	50 (14.1%)		17.0	60.8%
Neutrophil to lymphocyte ratio		0.001
≤4.0	131 (36.9%)		12.4	50.3%
>4.0	177 (49.9%)		5.6	30.4%
Unknown	47 (13.2%)		19.0	60.6%
Primary tumor site
Lung	152 (42.8%)		7.0	35.7%
Prostate	39 (11.0%)		28.0	68.6%
Breast	38 (10.7%)		9.3	38.4%
Colorectal	19 (5.4%)		8.8	39.0%
Uterus	17 (4.8%)		16.3	55.8%
Esophagus/gastric	14 (3.9%)		4.4	15.5%
Unknown primary	13 (3.7%)		6.8	29.4%
Melanoma	12 (3.4%)		1.8	25.0%
Kidney	8 (2.3%)		18.4	62.5%
Pancreatic/hepatobiliary	8 (2.3%)		15.5	57.1%
Other (ovary, cervix, sarcoma, skin, bladder, pleura, head and neck, vulva)	35 (9.9%)		12.4	52.2%
Favorable primary site		0.003
Breast, prostate, or kidney	85 (23.9%)		18.4	54.3%
Others	270 (76.1%)		7.0	37.9%
Number of active tumors		<0.001
1–5	106 (29.9%)		22.4	66.1%
≥6	249 (70.1%)		6.1	31.0%
Liver metastases		<0.001
Yes	80 (22.5%)		4.3	13.7%
No	275 (77.5%)		11.8	49.2%
Bone only metastases		<0.001
Yes	80 (22.5%)		22.4	67.2%
No	275 (77.5%)		6.8	34.5%
Hospitalization within the prior 3 months		<0.001
Yes	204 (57.5%)		5.5	28.8%
No	151 (42.5%)		15.7	58.3%
Prior systemic therapy regimens for distant metastases		0.44
0–1	297 (83.7%)		9.3	42.1%
≥2	58 (16.3%)		8.8	40.9%
Radiation dose intensity (EQD2)		<0.001
≥40 Gy	195 (54.9%)		16.0	57.4%
<40 Gy	160 (45.1%)		3.8	22.2%

Abbreviations: ECOG, Eastern Cooperative Oncology Group; EQD2, equivalent dose in 2 Gy fractions.